Oncternal Therapeutics, Inc. (ONCT)

Market Cap	1.56M
Revenue (ttm)	2.16M
Net Income (ttm)	-34.58M
Shares Out	2.96M
EPS (ttm)	-11.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	644,135
Open	0.700
Previous Close	0.694
Day's Range	0.527 - 0.700
52-Week Range	0.527 - 13.200
Beta	1.20
Analysts	Buy
Price Target	10.00 (+1,798.98%)
Earnings Date	Nov 6, 2024

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (C...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: James Breitmeyer
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCT
• Website: https://www.oncternal.com

Financial Performance

In 2023, Oncternal Therapeutics's revenue was $785,000, a decrease of -47.32% compared to the previous year's $1.49 million. Losses were -$39.48 million, -10.62% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for ONCT stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 1,798.98% from the latest price.

Price Target

$10.0

(1,798.98% upside)

Analyst Consensus: Buy